The Latest Developments in Alzheimer’s Drugs Disease

New Treatments on the Horizon



Several promising new drugs for Alzheimer's disease are currently in clinical
trials. These experimental treatments target various aspects of Alzheimer's
pathology and may slow cognitive decline. If successful, they could expand
treatment options beyond the existing approved medications.



One class of medications in late-stage trials attempts to reduce amyloid
plaques in the brain, a pathological hallmark of Alzheimers
Drugs. Amyloid-beta is a protein fragment that aggregates into plaque
deposits between neurons. Several antibodies and small molecules aim to clear
amyloid or prevent its accumulation.



Aducanumab, an intravenous antibody from Biogen, showed signs of reducing
amyloid and slowing cognitive decline in phase 3 trials. However, questions
remain about the size and consistency of the treatment effect. Researchers are
analyzing additional data to determine if the Alzheimer’s drugs provide a real
clinical benefit.



Another anti-amyloid antibody, donanemab from Eli Lilly, also targets a form of
amyloid thought to be especially toxic. Early phase 2 data found it
significantly reduced amyloid and slowly cognitive decline. A large phase 3
study is ongoing to confirm these initial positive results.

Get More Insights on- Alzheimers
Drugs